Novo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly alternative to ...

Novo Nordisk is set to introduce Awiqli, an innovative once-weekly insulin, in India shortly. This remarkable treatment drastically cuts do...

Under SEBI's T+1 settlement cycle, investors must purchase a company's shares at least one trading day before the record date to ensure the...

SpaceX has acquired AI coding assistant Cursor for $60 billion in an all-stock deal, significantly bolstering its AI ambitions. This move p...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

As many as 31 companies, including HDFC Bank, Tata group firms and Brigade Enterprises, will turn ex-record date for dividends and bonus is...

Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...

Elon Musk's SpaceX, which is readying for a closely watched IPO this week, said in April it had ⁠secured an ⁠option to either acquire code-...

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...

Emcure Pharmaceuticals and Sanofi India have announced a distribution agreement. Emcure will promote Sanofi India's oral anti-diabetic prod...

Shares of Sanofi Consumer Healthcare India made their market debut on Friday, listing on both the NSE and BSE. On its first day of trading,...

A Sanofi spokesperson told ET that a glut of supplies added during Covid-19 and the struggle to win contracts from Unicef for its critical ...

Hrosz will transition from being Sanofi’s general manager, Consumer Healthcare business in Brazil to his new role in India as soon as the a...

Sanofi India’s counter fell to a low of Rs 7,159 as against the previous close of Rs 7,280.40 on the National Stock Exchange.

Sanofi, which made $38.8 billion of sales in 2018, is a major manufacturer of vaccines, insulin, cancer treatments and cardiovascular drugs.

Biotech firm Genzyme Corp. says its board of directors is rejecting Sanofi-Aventis SA's $69 a share offer and recommending Genzyme sharehol...

French drug maker Sanofi-Aventis is likely to make an formal offer to acquire US-based biotech company Genzyme for USD 19 billion, says a m...